Objective To evaluate the safety and efficacy of gefitinib as second-line or even third-line
treatment for previously treated patients with locally advanced or metastatic non-small cell …

Objective To evaluate the efficacy and safety of gefitinib for the treatment of advanced non-
small cell lung cancer (NSCLC). Methods 125 patients with advanced NSCLC who had …

PURPOSE: This phase II single arm, open label study was designed to evaluate the efficacy
and toxicity of oral gefitinib (250mg) daily in previously untreated patients with advanced …

Objective To investigate the efficacy, time to progression, survival time and toxicity of
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor Gefitinib (Iressa), a target …

The aim of this study was to evaluate the efficacy and safety of gefitinib as a first-line therapy
for advanced non-small cell lung cancer (NSCLC). Patients with advanced NSCLC who did …

Objective To observe the efficacy, median survival time, time to progression, quality of life
and adverse effect of gefitinib (IRESSA) in the treatment for refractory advanced non-small …

Background The objective of this study was to evaluate the efficacy and toxicity of gefitinib as
a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Methods …

OBJECTIVE: To assess the efficacy and toxicity of gefitinib as a single agent treatment in
Chinese patients with advanced non-small cell lung cancer (NSCLC). METHODS: Forty-five …

Objective To evaluate the efficacy, target population and influencing factors of Gefitinib in
patients with non-small-cell lung cancer (NSCLC) pretreated with platinum. Methods …

Methods Clinical data of 256 gefitinib-treated Chinese NSCLC patients from two existing
clinical trials were analyzed. Univariate and multivariate analyses were performed to …